Fabienne Escande

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas

Romain Appay, Caroline Dehais, Claude‐Alain Maurage et al. · Neuro-Oncology · 2019 · 286 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Myoclonic absence epilepsy with photosensitivity and a gain of function mutation in glutamate dehydrogenase

Nadia Bahi‐Buisson, Sandra Sabbagh, Christine Soufflet et al. · Seizure · 2008 · 49 citations · Full text

Medicine, Genetics, Neurology +16

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients

Clotilde Descarpentries, Frédéric Leprêtre, Fabienne Escande et al. · Journal of Thoracic Oncology · 2018 · 42 citations · Full text

Medicine, Genetics, Oncology +13

Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors—towards individualized tumor treatment?

Carole Ramirez, Clive Bowman, Claude‐Alain Maurage et al. · Neuro-Oncology · 2010 · 41 citations · Full text

Medicine, Genetics, Oncology +17

A new pancreatic adenocarcinoma‐derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms

Elsa Hadj Bachir, Charles Poiraud, Sonia Paget et al. · Biology of the Cell · 2021 · 31 citations · Full text

Medicine, Oncology, Pharmacology +15